Geneoscopy’s novel stool-based RNA platform has demonstrated high accuracy in monitoring Crohn’s disease, according to recent findings. This innovative technology analyzes RNA biomarkers from stool samples to assess disease activity, offering a non-invasive alternative for monitoring patients. The platform’s ability to provide precise and actionable insights makes it a promising tool for clinicians in managing Crohn’s disease effectively.
Keep Reading
Add A Comment